Zeposia (ozanimod) is not safe to take while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can take the drug during this time.

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales.

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

I rely on biologics and infusions. I receive Entyvio every four weeks and take Zeposia daily alongside my other medications, which are crucial for managing my Crohn’s, Colitis, IBS, IBD and ...

Other drugs like Zeposia and Krazati should also contribute to top-line growth. BMY recently won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the ...

BMY’s Growth Portfolio Fuels Top Line in Q4 BMY’s Growth Portfolio comprises drugs like Opdivo, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Abecma, Sotyku, Krazati ...

Copaxone (glatiramer acetate injection) has potential interactions with other medications. These interactions could cause harmful effects. Copaxone is used in adults to treat relapsing forms of ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...